Follicular lymphoma (FL) is a clinically heterogeneous disease. The need for treatment,
treatment sequencing, number of treatment lines, and its association with survival have not …

Methods We identified all patients diagnosed with FL in the nationwide Swedish Lymphoma
register (coverage> 95%) during the period 2007 to 2014, with follow-up through 2020 …

We assessed stage-specific trends in primary therapy and relative survival among adult
follicular lymphoma (FL) patients diagnosed in the Netherlands between 1989–2016 (N …

Background: Follicular lymphoma (FL) patients may receive many lines of treatment (LoTs)
to maintain disease control. Current clinical outcomes in later LoTs (≥ 3 rd) are not well …

In follicular lymphoma (FL), progression of disease≤ 24 months (POD24) has emerged as
an important prognostic marker for overall survival (OS). We aimed to investigate survival …

Background: Follicular lymphoma (FL) is an indolent, yet incurable disease, and patients
often require several lines of therapy throughout their lifetime (Batlevi et al. Blood Cancer J …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …

Background: Observation or “wait and watch”(W/W) strategy remains a viable option in the
rituximab era for asymptomatic, stage II-IV, low-tumor burden patients with FL grade 1-2, 3A …

The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …

Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a
number of highly effective therapies. Patients and methods: We set out to determine …